# GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia

> **NCT01518517** · PHASE2,PHASE3 · COMPLETED · sponsor: **ERYtech Pharma** · enrollment: 85 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse

## Interventions

- **DRUG:** GRASPA
- **DRUG:** L-asparaginase

## Key facts

- **NCT ID:** NCT01518517
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-09
- **Final completion:** 2016-10
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518517, "GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01518517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*